Abstract:BACKGROUND-AIMPharmacogenetics is a discipline oriented to the study of the genetic basis of interindividual differences in the response to drugs, both at the level of efficacy and safety.One of the most widely used applications of Pharmacogenetics in clinical practice is the genetic test for HLA-B*5701 in patients who are going to start treatment with abacavir, due to its relationship with the hypersensitivity reaction it produces.Other adverse reactions of this type are: Relationship HLA-B15.02 with Steven-Johnson Syndrome and toxic epidermal necrolysis by carbamazepine, relationship HLA-B58.01 with Hypersensitivity Syndrome, Steven Johnson Syndrome and toxic epidermal necrolysis by allopurinol, relationship HLA-B35 with skin eruption by nevirapine and relationship HLA-B13.01 with hypersensitivity reaction induced by dapsone (DIHR).The objective of the study is to determine the prevalence of the HLA-B57.01 allele and the HLA-B35.05,HLA-B58.01,HLA-B15.02 and HLA-B13.01 alleles associated with adverse drug reactions in our healthcare area. METHODSDescriptive observational study of patients with HIV diagnosis, with request for genotyping HLA-B57.01 in our hospital area between July 2016 and September 2019 They were a total of 613 patients.Maxwell® 16 System, Blood DNA Purification System, was used to isolate the DNA in an automated way, which was later amplified by PCR.A strip probe assay, INNO-LiPAHLA-B Update Plus, was then used to determine the molecular typing of human leukocyte antigen (HLA) B alleles.The results were analyzed using Excel. RESULTSTo determine the prevalence of HLA-B alleles, an Excel database was created with a total of 613 samples.A prevalence of 3.75% was found for the HLA B57.01 allele.The prevalences of the other alleles with their respective confidence intervals (IC95%) and number of patients are detailed below: HLA-B 57.01 3,75% (2,51-5,57) 23 patients, HLA-B 58 0,82% (0,35-1,89) 5 patients, HLA-B35 9,79% (7,68-12,40) 60 patients, HLA-B15 1,14% (0,55-2,34) 7 patients and HLA-B13 1,63% (0,89-2,98) 10 patients. CONCLUSIONSThe calculated prevalences are lower than those described by other studies, such as the PREDICT-1 study with the participation of 15 European countries.We also found a high prevalence of the HLA-B35 allele, associated with adverse reactions to Nevirapine, more particularly the skin eruption induced by this second line antiretroviral in Spain.This high prevalence of HLA-B alleles associated with drug intolerance in our HIV population suggests that the determination of these alleles may be of great importance and utility in routine clinical practice in the at-risk population.

[Pharmacogenetic research in the association between human leukocyte antigen and adverse drug reactions].

Update on HLA-B*15:02 allele associated with adverse drug reactions

HLA Association with Drug-Induced Adverse Reactions

HLA Allele-Restricted Immune-Mediated Adverse Drug Reactions: Framework for Genetic Prediction.

Single Nucleotide Polymorphisms in the Regulatory Regions of the HLA-DRB-expressed Genes

Impact of New Genomic Technologies on Understanding Adverse Drug Reactions

Genotyping HLA alleles to predict the development of Severe cutaneous adverse drug reactions (SCARs): state-of-the-art

Advance on the Association of Drug-induced Liver Injury and HLA Gene Polymorphism

HLADR: a database system for enhancing the discovery of biomarkers for predicting human leukocyte antigen-mediated idiosyncratic adverse drug reactions.

Erratum To: Studies on Abacavir-Induced Hypersensitivity Reaction: a Successful Example of Translation of Pharmacogenetics to Personalized Medicine

The association between HLA-B variants and amoxicillin-induced severe cutaneous adverse reactions in Chinese han population

Drug-Induced Skin Adverse Reactions: The Role of Pharmacogenomics in Their Prevention

Genetic Literacy Series: Clinical Application of Pharmacogenetics for Adverse Reactions to Antiepileptic Drugs

Toxicology, Including Therapeutic Drug Monitoring

Structural and Energetic Insights into the Intermolecular Interaction among Human Leukocyte Antigens, Clinical Hypersensitive Drugs and Antigenic Peptides

Research on Susceptible Genes and Immunological Pathogenesis of Cutaneous Adverse Drug Reactions in Chinese Hans

Genophenotypic Factors and Pharmacogenomics in Adverse Drug Reactions

Associations Between Human Leukocyte Antigen Polymorphisms and Hypersensitivity to Antiretroviral Therapy in Patients with Human Immunodeficiency Virus: a Meta-Analysis.

Association Between HLA-B∗46:01 and Cutaneous Adverse Drug Reactions in Han Chinese

Using human genetics to improve safety assessment of therapeutics

Impact of HLA-B*58:01 allele and allopurinol-induced cutaneous adverse drug reactions: evidence from 21 pharmacogenetic studies